Stock 2487 CUTIA THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Cutia Therapeutics

Equities

2487

KYG2606C1006

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:05 2024-05-31 am EDT 		5-day change 1st Jan Change
7.2 HKD +2.86% Intraday chart for Cutia Therapeutics -9.43% -34.43%
May. 31 Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress MT
May. 30 Cutia Therapeutics Obtains Clinical Trial Approval in China for Dermatitis Drug MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CUTIA THERAPEUTICS Stock Cutia Therapeutics
-34.43% 281M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
B+
NOVARTIS AG Stock Novartis AG
+9.78% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
A+
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2487 Stock
  4. Ratings Cutia Therapeutics